261 related articles for article (PubMed ID: 30690076)
1. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
[TBL] [Abstract][Full Text] [Related]
2. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS
Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318
[TBL] [Abstract][Full Text] [Related]
3. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
[TBL] [Abstract][Full Text] [Related]
4. Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.
MacArthur TA; Fahy AS; Jakub JW
Am Surg; 2021 Jun; 87(6):849-854. PubMed ID: 34060947
[TBL] [Abstract][Full Text] [Related]
5. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
[TBL] [Abstract][Full Text] [Related]
6. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
8. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.
Monga V; Miller BJ; Tanas M; Boukhar S; Allen B; Anderson C; Stephens L; Hartwig S; Varga S; Houtman J; Wang L; Zhang W; Jaber O; Thomason J; Kuehn D; Rajput M; Metz C; Zamba KD; Mott S; Abanonu C; Bhatia S; Milhem M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330766
[TBL] [Abstract][Full Text] [Related]
10. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T
Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501
[TBL] [Abstract][Full Text] [Related]
11. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.
Sun L; Funchain P; Song JM; Rayman P; Tannenbaum C; Ko J; Mcnamara M; Marcela Diaz-Montero C; Gastman B
J Immunother Cancer; 2018 May; 6(1):36. PubMed ID: 29764498
[TBL] [Abstract][Full Text] [Related]
12. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM
J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544
[TBL] [Abstract][Full Text] [Related]
13. Future Directions and Challenges Facing Intralesional Immunotherapy With Talimogene Laherparepvec for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2021 Jan; 47(1):132-133. PubMed ID: 31574028
[No Abstract] [Full Text] [Related]
14. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
15. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
16. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
[TBL] [Abstract][Full Text] [Related]
17. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS
Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098
[TBL] [Abstract][Full Text] [Related]
18. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
19. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
20. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
Chitnis SD; Seim NB; Kendra K
J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]